Ethica Group, with the M&A Advisory team, assisted BioDue, an Italian excellence specialized in the development, production and marketing of food supplements, medical devices and cosmetics, already in the Armònia portfolio, in the sale of a majority stake to Riverside, a private equity with a global presence.
Founded in 1986 by the Benedetti family, BioDue is one of the main Italian players active in the development and production of food supplements and medical devices. The company produces niche formulations to third parties (“CDMO”), with a particular focus on liquids and in the probiotic, respiratory and gastrointestinal segments. BioDue also markets its own brand products in several therapeutic areas, including Pharcos (Dermatology), BiOfta (Ophthalmology), Agex (Aesthetics), River Pharma (Orthopedics) and IP Farma (Gynecology).
Riverside, starting from its entry into BioDue, intends to pursue a pan-European buy-and-build strategy and at the same time, with the participation and leadership of Riverside, BioDue aims to improve the one-stop-shop offer and expand the offer of pharmaceutical forms and therapeutic areas.